The FDA has approved Vertex Pharmaceuticals' Journavx, marking a significant milestone in developing nonopioid pain treatments. The first-in-class drug targets the NaV1.7 channel, blocking pain signals in the peripheral nervous system, to manage moderate to acute pain, offering an alternative to traditional opioids.